Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children

Trial Profile

Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate
  • Indications Meningococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline; Pfizer
  • Most Recent Events

    • 21 Sep 2017 Planned End Date changed from 10 Nov 2017 to 14 Nov 2017.
    • 21 Sep 2017 Planned primary completion date changed from 10 Nov 2017 to 14 Nov 2017.
    • 18 Apr 2017 Planned End Date changed from 1 Oct 2017 to 10 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top